奥马佐单抗
医学
哮喘
恶化
安慰剂
人口
不利影响
儿科
内科学
入射(几何)
随机对照试验
哮喘恶化
重症监护医学
免疫球蛋白E
免疫学
替代医学
抗体
病理
环境卫生
物理
光学
作者
Marc Humbert,Richard Beasley,Jon G. Ayres,Raymond G. Slavin,Jacques Hébert,Jean Bousquet,Kai-Michael Beeh,Silvia Martín Ramos,Giorgio Walter Canonica,S. Hedgecock,Howard Fox,M. Blogg,K. Surrey
出处
期刊:Allergy
[Wiley]
日期:2004-12-20
卷期号:60 (3): 309-316
被引量:1022
标识
DOI:10.1111/j.1398-9995.2004.00772.x
摘要
Background: Patients with severe persistent asthma who are inadequately controlled despite Global Initiative for Asthma (GINA) 2002 step 4 therapy are a challenging population with significant unmet medical need. We determined the effect of omalizumab on clinically significant asthma exacerbations (requiring systemic corticosteroids) in the first omalizumab study to exclusively enrol patients from this difficult‐to‐treat patient population. Methods: Following a run‐in phase, patients (12–75 years) inadequately controlled despite therapy with high‐dose inhaled corticosteroids (ICS) and long‐acting β 2 ‐agonists (LABA) with reduced lung function and a recent history of clinically significant exacerbations were randomized to receive omalizumab or placebo for 28 weeks in a double‐blind, parallel‐group, multicentre study. Results: A total of 419 patients were included in the efficacy analyses. The clinically significant asthma exacerbation rate (primary efficacy variable), adjusted for an observed relevant imbalance in history of clinically significant asthma exacerbations, was 0.68 with omalizumab and 0.91 with placebo (26% reduction) during the 28‐week treatment phase ( P = 0.042). Without adjustment, a similar magnitude of effect was seen (19% reduction), but this did not reach statistical significance. Omalizumab significantly reduced severe asthma exacerbation rate (0.24 vs 0.48, P = 0.002) and emergency visit rate (0.24 vs 0.43, P = 0.038). Omalizumab significantly improved asthma‐related quality of life, morning peak expiratory flow and asthma symptom scores. The incidence of adverse events was similar between treatment groups. Conclusions: In patients with inadequately controlled severe persistent asthma, despite high‐dose ICS and LABA therapy, and often additional therapy, omalizumab significantly reduced the rate of clinically significant asthma exacerbations, severe exacerbations and emergency visits. Omalizumab is effective and should be considered as add‐on therapy for patients with inadequately controlled severe persistent asthma who have a significant unmet need despite best available therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI